Dark Forest Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Dark Forest Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,071	Closed	-$209K	–	1077
2025 Q4	$209K	Buy	+9,071	New	+$298K	0.01%	918
2025 Q1	–	Sell	-10,916	Closed	-$459K	–	1399
2024 Q4	$459K	Buy	+10,916	New	+$542K	0.07%	476
2022 Q4	–	Sell	-260	Closed	-$11K	–	1433
2022 Q3	$11K	Buy	+260	New	+$13.4K	﹤0.01%	728
2022 Q1	–	Sell	-64	Closed	-$5K	–	1678
2021 Q4	$5K	Buy	+64	New	+$5.21K	﹤0.01%	1176
2021 Q3	–	Sell	-370	Closed	-$35K	–	1494
2021 Q2	$35K	Buy	+370	New	+$38.5K	0.02%	494

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Dark Forest Capital Management's RARE Position: Q1 2026 in Review

Dark Forest Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 9,071 shares — an estimated $209K sold.

Dark Forest Capital Management first reported a position in RARE in Q2 2021 and held it in 5 quarters. The position peaked at $459K in Q4 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Dark Forest Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Dark Forest Capital Management sold 9,071 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $209K.
Dark Forest Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 5 quarters.
Dark Forest Capital Management's Ultragenyx Pharmaceutical position peaked at $459K in Q4 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Dark Forest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.